Stay updated on Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial
Sign up to get notified when there's something new on the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page.

Latest updates to the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThis updates the displayed revision/version indicator for the page from **v3.5.2** to **v3.5.3**.SummaryDifference0.1%

- Check20 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedFooter revision label updated to v3.5.0. The previous v3.4.3 label was removed.SummaryDifference0.1%

- Check56 days agoChange Detected- Revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check85 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1; the visible content and functionality of the page appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page.